113 terminated. 113 Phase 3, 15 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 113 | Terminated 113 |
| Phase 2 | 15 | Terminated 15 |
Follow Liver Diseases: new trials by email Literature Review of Liver Diseases trials Research Report on Liver Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate FDC tablet (OCA 5 mg + BZF 400 mg SR) - Primary Biliary Cholangitis | Phase 3 | Terminated | Intercept Pharmaceuticals | 62 | 2024-07-01 | 2026-06-08 |
| NEPH-ROSIS (NEPHrology in CirRhOSIS) Pilot Trial: A Trial to Treat Acute Kidney Injury Among Hospitalized Cirrhosis Patients MAP-Target Algorithm - Acute Kidney Injury, Cirrhosis | Phase 2 / Phase 3 | Terminated | University of California, San Francisco | 14 | 2024-02-01 | 2026-09-24 |
| Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7 Regorafenib in combination with pembrolizumab, Loco-regional therapy - Carcinoma, Hepatocellular | Phase 3 | Terminated | Translational Research in Oncology | 45 | 2023-10-11 | 2026-03-09 |
| Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial. HAIC, TACE, FOLFOX - Hepatocellular Carcinoma | Phase 2 / Phase 3 | Terminated | Peking University | 18 | 2021-12-24 | 2025-12-18 |
| Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease ALXN1840, Standard of Care - Wilson Disease | Phase 3 | Terminated | Alexion Pharmaceuticals, Inc. | 40 | 2021-09-13 | 2024-10-23 |
| A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy Atezolizumab, Bevacizumab - Carcinoma, Hepatocellular | Phase 3 | Terminated | Hoffmann-La Roche | 100 | 2021-05-04 | 2025-05-08 |
| Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis belapectin, Placebo - Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis | Phase 2 / Phase 3 | Terminated | Galectin Therapeutics Inc. | 357 | 2020-06-25 | 2026-06-30 |
| Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012) Lenvatinib, Pembrolizumab, Oral Placebo - Carcinoma, Hepatocellular | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 480 | 2020-05-22 | 2026-09-03 |
| Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant Stereotactic Body Radiation Therapy (SBRT), Trans-Arterial Chemoembolization (TACE), Doxorubin - Hepatocellular Carcinoma, HCC | Phase 3 | Terminated | Lahey Clinic | 9 | 2020-03-01 | 2024-08-28 |
| A Study of Secukinumab Treatment in Patients With Plaque Psoriasis and Coexisting Non-alcoholic Fatty Liver Disease (NAFLD) Investigational Arm - secukinumab, Control Arm - placebo - Plaque Psoriasis, Non-alcoholic Fatty Liver Disease | Phase 3 | Terminated | Novartis Pharmaceuticals | 10 | 2020-02-19 | 2024-02-29 |
| Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors Best Practice, Entecavir, Tenofovir Alafenamide - Hepatitis B Infection, Malignant Solid Neoplasm | Phase 3 | Terminated | SWOG Cancer Research Network | 4 | 2020-01-17 | 2024-05-20 |
| Phase III, Efficacy and Safety of "Kamada-AAT for Inhalation" Alpha 1-Antitrypsin, Placebo - Alpha 1-Antitrypsin Deficiency | Phase 3 | Terminated | Kamada, Ltd. | 98 | 2019-11-25 | 2026-08-12 |
| Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5% SMT + PE-A 5%, Standard Medical Treatment - Acute-On-Chronic Liver Failure | Phase 3 | Terminated | Instituto Grifols, S.A. | 274 | 2019-06-17 | 2026-06-04 |
| Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease ALXN1840, SoC Therapy - Wilson Disease | Phase 3 | Terminated | Alexion Pharmaceuticals, Inc. | 214 | 2018-02-22 | 2024-06-17 |
| The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects Icaritin, Sorafenib Tosylate Tablets - Hepatocellular Carcinoma (HCC) | Phase 3 | Terminated | Beijing Shenogen Biomedical Co., Ltd | 89 | 2017-09-20 | 2023-02-08 |
| A Long Term Follow-up Study in Participants Treated in a Preceding Phase 2 or 3 Study With a Regimen Containing Odalasvir and AL-335 With or Without Simeprevir for the Treatment of Hepatitis C Virus (HCV) Infection No Treatment - Hepatitis C | Phase 3 | Terminated | Janssen Research & Development, LLC | 24 | 2017-04-10 | 2025-02-03 |
| AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH) Placebo, Cenicriviroc - Nonalcoholic Steatohepatitis | Phase 3 | Terminated | Tobira Therapeutics, Inc. | 1778 | 2017-04-05 | 2022-03-10 |
| Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis SEL, Placebo to match SEL 6 mg, Placebo to match SEL 18 mg - Nonalcoholic Steatohepatitis | Phase 3 | Terminated | Gilead Sciences | 808 | 2017-02-13 | 2020-06-29 |
| Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) SEL, Placebo to match SEL 6 mg, Placebo to match SEL 18 mg - Nonalcoholic Steatohepatitis | Phase 3 | Terminated | Gilead Sciences | 883 | 2017-01-30 | 2020-05-07 |
| Proton Pump Inhibitor Plus Propranolol Versus Proton Pump Inhibitor Alone on Peptic Ulcer Healing in Patients With Liver Cirrhosis Proton-pump inhibitor, Propranolol+Proton-pump inhibitor - Liver Cirrhosis, Peptic Ulcer | Phase 2 / Phase 3 | Terminated | Taipei Veterans General Hospital, Taiwan | 10 | 2016-12-26 | 2020-06-23 |
Showing 20 of 113. Sign in to see all of them.
Carcinoma, Hepatocellular (30) · Hepatitis C (19) · Hepatitis C, Chronic (18) · Hepatitis B (15) · Liver Cirrhosis (11) · Liver Neoplasms (11) · Fibrosis (9) · Non-alcoholic Fatty Liver Disease (8) · Hepatitis B, Chronic (7) · HIV Infections (4) · Hypertension, Portal (4) · Neoplasms (4) · Carcinoma (3) · Esophageal and Gastric Varices (3)
Digestive System Diseases (112) · Pathological Conditions, Signs and Symptoms (52) · Pathologic Processes (50) · Hepatitis (49) · Hepatitis, Viral, Human (49) · Infections (49) · Virus Diseases (49) · Blood-Borne Infections (48) · Communicable Diseases (48) · Digestive System Neoplasms (32) · Neoplasms by Site (32) · RNA Virus Infections (32) · Disease Attributes (31) · Flaviviridae Infections (30)
Ribavirin (17) · peginterferon alfa-2a (12) · peginterferon alfa-2b (9) · Sorafenib (7) · clevudine (6) · Tenofovir (5) · entecavir (4) · Ethiodized Oil (3) · N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide (3) · Telbivudine (3) · adefovir (3) · telaprevir (3) · Doxorubicin (2) · Fluorouracil (2) · Gemcitabine (2)
Merck Sharp & Dohme LLC (7) · French National Agency for Research on AIDS and Viral Hepatitis (5) · Novartis Pharmaceuticals (4) · Sanofi (4) · Assistance Publique - Hôpitaux de Paris (3) · Bukwang Pharmaceutical (3) · Gilead Sciences (3) · GlaxoSmithKline (3) · Rennes University Hospital (3) · University Health Network, Toronto (3) · Alexion Pharmaceuticals, Inc. (2) · Boston Scientific Corporation (2) · Bristol-Myers Squibb (2) · Debiopharm International SA (2) · Hoffmann-La Roche (2)
United States (50) · France (34) · Spain (32) · Canada (31) · Germany (30) · Italy (26) · United Kingdom (25) · South Korea (24) · Belgium (23) · Taiwan (23) · Australia (21) · Poland (17) · Puerto Rico (17) · China (14) · Argentina (12)
Hyo-Suk Lee, MD. PhD (3) · Eric Bellissant, MD, PhD (2) · Alexander Kuo, MD (1) · Alexander Wilmer, MD, PhD (1) · Amanda Wieland, MD (1) · Amany Y Elkazaz (1)
PMID 21836029, PMID 30639779, PMID 30779990, PMID 31271665, PMID 32147362, PMID 33307033, PMID 36750244, PMID 17593061, PMID 17635375, PMID 17647293, PMID 17850410, PMID 18266997, PMID 19053983, PMID 20203173, PMID 20724077, PMID 22913681, PMID 23316013, PMID 23331661, PMID 23397536, PMID 24012941, PMID 24081937, PMID 24251922, PMID 24657396, PMID 25009371, PMID 25152207, PMID 25488963, PMID 25543678, PMID 26212068, PMID 27219495, PMID 28988687, PMID 29091342, PMID 30577864, PMID 31260793, PMID 31813633, PMID 32557715, PMID 32950590, PMID 33300372, PMID 34052255, PMID 34274514, PMID 34793868, PMID 35119481, PMID 35226112, PMID 35421228, PMID 37061109, PMID 37665565, PMID 38126958, PMID 39798578, PMID 40757786, PMID 8213790, PMID 9346731
2016 (4), 2008 (2), 2019 (2), 2005 (1), 2009 (1), 2015 (1), 2017 (1), K23CA115908 (1), M01RR000040 (1), P30CA124435 (1), P30DK050306 (1), U01DK082843 (1), U01DK082863 (1), U01DK082864 (1), U01DK082866 (1)